Literature DB >> 31516260

Correlation of baseline Portal pressure (hepatic venous pressure gradient) and Indocyanine Green Clearance Test With Post-transarterial Chemoembolization Acute Hepatic Failure.

Rohit Khisti1, Yashwant Patidar1, Lalit Garg1, Amar Mukund1, Sherin Sarah Thomas2, Shiv K Sarin3.   

Abstract

BACKGROUND: Liver failure (LF) is a serious complication of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). This could be influenced by the hemodynamic and functional status of the underlying cirrhotic liver. We evaluated baseline hepatic venous pressure gradient (HVPG) and indocyanine green (ICG) clearance as predictive factors for the development of LF in patients with liver cirrhosis undergoing TACE for HCC.
METHODS: Forty-two patients with cirrhosis and HCC, referred for TACE, were clinically evaluated including the assessment of Child Turcotte Pugh score (CTP), Model for End-Stage Liver Disease (MELD), HVPG measurement, and ICG retention test. Predictors of development of hepatic failure after TACE were determined.
RESULTS: In our study population, the mean age of the patients was 58 years, with mean CTP of 6.60 ± 1.149 and mean MELD score of 9.57 ± 2.923. The mean HVPG and ICG retention at 15 min was 13.57 ± 4.64 mmHg and 21.571 ± 12.434, respectively. Post-TACE Liver Failure (PTLF within 1 month after TACE) developed in 23.80% patients, whereas 76.19% patients did not have PTLF. The statistically significant preprocedure variables that might predict hepatic failure after TACE using univariate analysis were found to be high CTP, MELD score, ICG retention, HVPG, serum bilirubin, serum creatinine, alfa-fetoprotein levels, large tumor size, and low baseline serum albumin. On multivariate analysis, ICG was an independent factor predictive of hepatic failure after TACE.
CONCLUSION: Pretreatment evaluation of routine liver function is of fundamental importance before TACE. Baseline ICG retention test (ICG-R15) is a marker indicating the state of liver function in patients undergoing TACE and is an independent predictor for PTLF. Our study concludes that with a cutoff of 25, ICG-R15 has 92.9% accuracy, 90% sensitivity, and 87.5% specificity to predict hepatic failure after TACE.

Entities:  

Keywords:  BCLC, Barcelona Clinic Liver Cancer; HCC, Hepatocellular Carcinoma; HVPG; HVPG, Hepatic Venous Pressure Gradient; ICG clearance test; ICG, Indocyanine green; IRB, Institutional Review Board; LF, Liver Failure; MELD, Model for End-Stage Liver Disease; PHT, Portal Hypertension; PTLF, Post-TACE liver failure; RFA, Radiofrequency Ablation; ROC, Receiver operating characteristic curve; TACE; TACE, Transarterial chemoembolization

Year:  2018        PMID: 31516260      PMCID: PMC6728539          DOI: 10.1016/j.jceh.2018.09.004

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  17 in total

1.  The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma.

Authors:  Jia-Xin Li; Hong Wu; Ji-Wei Huang; Yong Zeng
Journal:  J Formos Med Assoc       Date:  2012-07-24       Impact factor: 3.282

2.  Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Yang Won Min; Jeong Kim; Seonwoo Kim; Young Kyung Sung; Jin Hee Lee; Geum-Youn Gwak; Yong Han Paik; Moon Seok Choi; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Joon Hyeok Lee
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

Review 3.  How much liver resection is too much?

Authors:  Emma J Mullin; Matthew S Metcalfe; Guy J Maddern
Journal:  Am J Surg       Date:  2005-07       Impact factor: 2.565

4.  Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension.

Authors:  Chiara Elia; Wilma Debernardi Venon; Davide Stradella; Silvia Martini; Franco Brunello; Alfredo Marzano; Giorgio Saracco; Mario Rizzetto
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-07       Impact factor: 2.566

5.  Impact of non-congestive graft size in living donor liver transplantation: new indicator for additional vein reconstruction in right liver graft.

Authors:  Hideya Kamei; Yasuhiro Fujimoto; Shunji Nagai; Ryuichiro Suda; Hidekazu Yamamoto; Tetsuya Kiuchi
Journal:  Liver Transpl       Date:  2007-09       Impact factor: 5.799

6.  Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis.

Authors:  Yun Ku Cho; Jae Kyun Kim; Wan Tae Kim; Jin Wook Chung
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

7.  Acute portal hemodynamics and cytokine changesfollowing selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma.

Authors:  Laurent Spahr; Christoph Becker; Jérôme Pugin; Pietro E Majno; Antonine Hadengue
Journal:  Med Sci Monit       Date:  2003-09

8.  Accuracy of indocyanine green pulse spectrophotometry clearance test for liver function prediction in transplanted patients.

Authors:  Chung-Bao Hsieh; Chung-Jueng Chen; Teng-Wei Chen; Jyh-Cherng Yu; Kuo-Liang Shen; Tzu-Ming Chang; Yao-Chi Liu
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

9.  Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events.

Authors:  Abbas Ali Tasneem; Zaigham Abbas; Nasir Hassan Luck; Syed Mujahid Hassan; Syed Muhammad Faiq
Journal:  J Pak Med Assoc       Date:  2013-02       Impact factor: 0.781

Review 10.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin
Journal:  Semin Radiat Oncol       Date:  2003-07       Impact factor: 5.934

View more
  3 in total

Review 1.  Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.

Authors:  Franziska Hauth; Hannah J Roberts; Theodore S Hong; Dan G Duda
Journal:  Int J Mol Sci       Date:  2022-02-09       Impact factor: 5.923

2.  Hepatoprotective role of peroxisome proliferator-activated receptor-α in non-cancerous hepatic tissues following transcatheter arterial embolization.

Authors:  Peiyu Yang; Zhengliang Li; Wei Du; Chunhua Wu; Wencui Xiong
Journal:  Open Life Sci       Date:  2022-08-11       Impact factor: 1.311

3.  Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study.

Authors:  Min Yuan; Tian-You Chen; Xiao-Rong Chen; Yun-Fei Lu; Jia Shi; Wen-Si Zhang; Chen Ye; Bo-Zong Tang; Zong-Guo Yang
Journal:  World J Clin Cases       Date:  2022-08-26       Impact factor: 1.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.